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ABSTRACT
Study queStion
Can routine antenatal blood pressure measurements 
between 20 and 36 weeks’ gestation contribute to the 
prediction of pre-eclampsia and its associated adverse 
outcomes?   
MethodS
This study used repeated antenatal measurements of 
blood pressure from 12 996 women in the Avon 
Longitudinal Study of Parents and Children (ALSPAC) to 
develop prediction models and validated these in 3005 
women from the Southampton Women’s Survey (SWS). 
A model based on maternal early pregnancy 
characteristics only (BMI, height, age, parity, smoking, 
existing and previous gestational hypertension and 
diabetes, and ethnicity) plus initial mean arterial 
pressure was compared with a model additionally 
including current mean arterial pressure, a model 
including the deviation of current mean arterial 
pressure from a stratified normogram, and a model 
including both at different gestational ages from 20-36 
weeks.
Study anSwer and liMitationS
The addition of blood pressure measurements from 28 
weeks onwards improved prediction models compared 
with use of early pregnancy risk factors alone, but they 
contributed little to the prediction of preterm birth or 
small for gestational age. Though multiple imputation 
of missing data was used to increase the sample size 
and minimise selection bias, the validation sample 
might have been slightly underpowered as the number 
of cases of pre-eclampsia was just below the 
recommended 100. Several risk factors were self 
reported, potentially introducing measurement error, 
but this reflects how information would be obtained in 
clinical practice.
what thiS Study addS
The addition of routinely collected blood pressure 
measurements from 28 weeks onwards improves 
predictive models for pre-eclampsia based on 
blood pressure in early pregnancy and other 
characteristics, facilitating a reduction in scheduled 
antenatal care.
Funding, CoMpeting intereStS, data Sharing
UK Wellcome Trust, US National Institutes of Health, 
and UK Medical Research Council. Other funding 
sources for authors are detailed in the full online 
paper. With the exceptions of CM-W, HMI, and KMG 
there were no competing interests.
Introduction
Pre-eclampsia is the most severe form of hypertensive 
disorder of pregnancy and is associated with maternal 
and fetal mortality,1 2  intrauterine growth restriction, 
and preterm birth.3-5  It is defined as de novo high blood 
pressure occurring after 20 weeks’ gestation in conjunc-
tion with proteinuria,6  but these symptoms can develop 
swiftly, within days of a normal antenatal assessment, 
and deficiencies in care have previously been reported 
in relation to maternal and fetal deaths attributable to 
pre-eclampsia in the United Kingdom.7 8  Although 
there is no known cure for pre-eclampsia other than 
delivery of the baby,9  decisions such as whether to 
expectantly monitor or to deliver are important for both 
maternal and fetal outcome.10  Therefore it is important 
to be able to identify women at risk as early in preg-
nancy as possible to allow for adequate surveillance 
and early detection of disease.8  We,11  and others,12 
have shown that before the diagnostic threshold for 
pre-eclampsia is met, the pattern of change in blood 
pressure during pregnancy differs between women who 
remain normotensive and those who subsequently 
develop pre-eclampsia. Specifically women who go on 
to experience pre-eclampsia have a higher initial blood 
pressure and a steeper increase after the mid-preg-
nancy nadir. A greater increase in blood pressure across 
pregnancy is also associated with a shorter gestation 
and a lower birthweight baby.4 13 14
Several prediction models have shown the value 
of using blood pressure recorded at the first visit to 
WhAT IS AlReAdy knoWn on ThIS TopIC
Blood pressure measured at the booking appointment for antenatal care is often 
used in combination with other clinical risk factors in prediction models to identify 
women at risk of developing pre-eclampsia later in pregnancy
Studies that have compared patterns of change in blood pressure across pregnancy 
have shown that, as well as having a higher initial blood pressure, women who develop 
pre-eclampsia have a steeper rise in blood pressure in the second half of pregnancy
WhAT ThIS STudy AddS
The addition of routinely collected measurements of blood pressure taken in the 
second half of pregnancy to prediction models for pre-eclampsia improves their 
performance compared with using early risk factors alone
Use of these prediction models sequentially at each antenatal appointment to rule 
out women who are at low risk of developing pre-eclampsia could enable these 
women to be transferred to a reduced antenatal care schedule
Blood pressure measurements in the second half of pregnancy are of little benefit 
in the prediction of preterm birth or small for gestational age offspring
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the  antenatal clinic alongside other maternal 
 characteristics to predict the later development of 
pre-eclampsia.15-22  As blood pressure is routinely 
measured on repeated occasions during pregnancy 
in most high income countries, and could also be 
feasibly measured in low and middle income coun-
tries, the incorporation of subsequent measure-
ments and the trajectory of change in blood pressure 
in clinical prediction models could add additional 
value and improve the information available to make 
decisions about care. As well as identification of 
women at high risk who would benefit from inten-
sive monitoring to prevent the adverse outcomes 
associated with pre-eclampsia, it might also be ben-
eficial to be able to identify a group of women at low 
risk and transfer them to a reduced schedule of ante-
natal appointments.23
We have previously developed stratified normal refer-
ence ranges for blood pressure, which allow for a differ-
ent expected trajectory of blood pressure for different 
subgroups of women.24 In this study we assessed and 
externally validated the predictive ability of blood pres-
sure measurements at different gestational ages, and 
their comparison with our reference ranges, to identify 
women at higher and low risk of pre-eclampsia using 
two prospective cohort studies from the UK. We addi-
tionally investigated whether such measurements were 
able to identify pregnancies at risk of preterm birth and 
small for gestational age babies, as these are two of the 
perinatal outcomes that are most commonly associated 
with pre-eclampsia.
This paper conforms to TRIPOD guidelines.25
Methods
avon longitudinal Study of parents and Children 
(alSpaC)
For the development of the prediction models we used 
the Avon Longitudinal Study of Parents and Children 
(ALSPAC), a prospective birth cohort study that 
recruited women with expected delivery dates between 
1 April 1991 and 31 December 1992 living in a defined 
area of Avon during pregnancy. The study has been 
described in full elsewhere,26 and the study website 
contains details of available data (www.bris.ac.uk/
alspac/researchers/data-access/data-dictionary). A 
total of 14 541 women were enrolled, 13 678 had a single-
ton pregnancy resulting in a live birth, and data on 
measurements of blood pressure were available for 
12 996 of these women.
Obstetric measurements in ALSPAC
Six trained research midwives abstracted all measure-
ments of blood pressure and proteinuria that were 
taken as part of routine antenatal care by midwives or 
obstetricians from the women’s obstetric records. There 
was no variation between midwives in mean values of 
the data abstracted, and error rates were consistently 
<1% in repeated data entry checks. Measurements were 
taken once in women in the seated position with the 
appropriate cuff size, with Korotkoff phase V used for 
diastolic blood pressure.
Maternal and offspring characteristics in ALSPAC
Maternal age at delivery and sex of the baby were 
obtained from obstetric records. Maternal weight and 
height before pregnancy, together with parity, smoking 
status, education, hypertension, and diabetes before 
the index pregnancy and ethnicity and household 
social class were obtained from questionnaires admin-
istered during pregnancy. Smoking during pregnancy 
was classed as “never” or “any smoking” for women 
who reported smoking either in the first three months 
of pregnancy or within two weeks of the 18 week ques-
tionnaire. Women who reported ever having hyperten-
sion outside of pregnancy were classed as having 
essential hypertension, while women who reported 
having hypertension only in pregnancy were classed as 
having previous gestational hypertension. Similarly, 
women who reported having ever had diabetes outside 
of pregnancy were defined as having diabetes while 
women who reported having diabetes only in a previ-
ous pregnancy were defined as having previous gesta-
tional diabetes.
Southampton women’s Survey (SwS)
In accordance with recent guidelines on the develop-
ment and assessment of prognostic models,27  we exter-
nally validated our prediction models in a further 
dataset. The Southampton Women’s Survey is a pro-
spective cohort study that recruited non-pregnant 
women through general practices in Southampton 
between April 1998 and September 2002. Full details of 
the study have been published previously.28 The study 
enrolled 12 583 women, of whom 3158 became pregnant 
and had delivered a singleton liveborn infant by the end 
of 2007. Obstetric blood pressure measurements were 
available for 3005 of these.
Obstetric measurements in Southampton Women’s 
Survey
A team of trained research midwives abstracted all mea-
surements of blood pressure that were routinely col-
lected during pregnancy from the women’s obstetric 
records after delivery following a strict protocol. The 
measurements were ordered by time, and the data 
checked for consistency.
Maternal and offspring characteristics in 
Southampton Women’s Survey
Maternal age at delivery and sex of offspring were 
obtained from obstetric records. Information on 
maternal parity, education, social class, and ethnicity 
was obtained at the initial interview before pregnancy, 
and height was measured. At the 11 week interview the 
mothers reported pre-pregnancy weight, any diabetes 
in a previous pregnancy or outside of pregnancy, and 
high blood pressure in a previous pregnancy or out-
side of pregnancy. Smoking status was obtained 
during interviews at 11 and 34 weeks’ gestation and 
classified as “never smoked in pregnancy” or “any 
smoking in pregnancy.” An algorithm that incorpo-
rated information recorded before pregnancy and at 
six months  postpartum was used to estimate smoking 
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in pregnancy when data at one or both time points 
were missing.
Initial blood pressure and gestational age specific 
blood pressure in ALSPAC and SWS
As preliminary analysis suggested that mean arterial 
pressure was a stronger predictor of each outcome 
than systolic blood pressure (SBP) or diastolic blood 
pressure (DSP) separately, we used this as our mea-
sure of blood pressure in prediction models. This was 
defined as (SBP+2×DBP)/3. In both cohorts, the initial 
measurement of mean arterial pressure was defined 
as the first antenatal measurement, provided that 
this occurred before 18 weeks’ gestation. We also 
derived mean arterial pressure at 20, 25, 28, 31, 34, 
and 36 weeks’ gestation for each woman (following 
the standard schedule of antenatal appointments for 
nulliparous women used in the UK29), using the mea-
surement that was closest to this gestational age and 
within two weeks of it, or classifying the variable as 
missing if there was no measure within this gesta-
tional age range.
Pregnancy outcomes in ALSPAC and SWS
In ALSPAC pre-eclampsia was defined by the Interna-
tional Society for the Study of Hypertension in Preg-
nancy (ISSHP) criteria6 as systolic blood pressure ≥140 
mm Hg and/or diastolic blood pressure ≥90 mm Hg 
along with proteinuria of ≥1+ on urine dipstick testing 
occurring on two occasions after 20 weeks’ gestation. In 
SWS we used information on any diagnosis of pre-ec-
lampsia that was recorded in obstetric records to define 
preeclampsia. In both cohorts, we defined small for ges-
tational age as below the 10th centile of birth weight 
adjusted for gestational age at birth using internal stan-
dardisation by cohort. In ALSPAC the final clinical esti-
mate of the expected date of delivery was abstracted 
from the obstetric records and used to calculate gesta-
tional age at delivery. In SWS we used a computerised 
algorithm to derive gestational age using menstrual 
data (66%) or, when these were uncertain or discrepant 
with ultrasound assessments, fetal anthropometry in 
early pregnancy. Preterm birth was defined as birth 
before 37 weeks’ gestation.
Table A in appendix 1 gives a summary of definitions 
of all outcomes and predictor variables in ALSPAC and 
SWS for comparison.
Statistical analysis
Deriving expected trajectories of mean arterial 
pressure for each woman
In the first stage of model development we developed 
expected trajectories of mean arterial pressure across 
pregnancy, or normograms, in ALSPAC, similarly to 
those described previously.24  For the 9402 women in 
ALSPAC who had a normal pregnancy without pre-ec-
lampsia, essential hypertension, or diabetes, and 
delivered a term infant appropriate size for gestational 
age we used multilevel models to describe the trajec-
tory of change in mean arterial pressure using the 
observed repeated measurements across the whole of 
pregnancy and the exact gestational ages at measure-
ment. The multilevel models had two levels: measure-
ment occasion (level 1) within individual (level 2). We 
used restricted cubic splines with knots at 11, 18, 30, 36, 
and 40 weeks’ gestation to describe the shape of the 
trajectory as this was found to have the best fit to these 
data in previous analysis.24 We allowed for different 
average trajectories according to BMI category and 
smoking status by including appropriate interaction 
terms and fitted separate models for nulliparous and 
multiparous women.
For all women in the ALSPAC cohort (including 
non-normal pregnancies) we then obtained a normative 
value of mean arterial pressure at 20, 25, 28, 31, 34, and 
36 weeks’ gestation, which accounted for their parity 
and BMI before pregnancy and whether they smoked 
during pregnancy, and was conditional on their mean 
arterial pressure at their initial visit (before 18 weeks’ 
gestation). Appendix 2 gives further information on the 
derivation of this normative value.
Missing data
For both the ALSPAC and SWS datasets there were 
missing data on maternal characteristics and also for 
the derived values of initial mean arterial pressure and 
mean arterial pressure at 20, 25, 28, 31, 34, and 36 
weeks for some women. To increase power and mini-
mise selection bias in the second stage prediction 
models, we next used multivariable multiple imputa-
tion of missing data. Separate imputation models were 
used for the two cohorts, imputing to the full 12 996 
women in ALSPAC and 3005 women in SWS who had 
any measurements of mean arterial pressure in preg-
nancy. For each imputation model, we included all 
early pregnancy characteristics and derived mean 
arterial pressure values as well as the outcomes. We 
imputed any missing data for the normative values of 
mean arterial pressure passively from imputed early 
pregnancy characteristics and initial mean arterial 
pressure. For each imputation we generated 20 
imputed datasets and combined coefficient estimates 
across these using Rubin’s rules.30  31  Imputation of 
missing data in this way assumes that data are missing 
at random—that is, that any reasons for missingness 
are explained by the observed variables included in 
the imputation model.32 The assumption seems rea-
sonable here as most women will not be aware of their 
current blood pressure (only their previous values) so 
this is unlikely to influence their decision to have their 
blood pressure measured at any given gestational age. 
Full details of the imputation models are included in 
appendix 2.
Prediction of pre-eclampsia, preterm birth, and 
small for gestational age
In the second stage we used logistic regression to 
obtain separate prediction models for pre-eclampsia, 
preterm birth, and small for gestational age in ALSPAC 
based on the imputed datasets. Maternal predictors 
were selected from BMI before pregnancy, height, age 
≥35, parity, smoking, essential hypertension,  previous 
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gestational hypertension, diabetes, previous gesta-
tional diabetes, and non-white ethnicity. This set of 
predictors was chosen because of strong prior evi-
dence of their association with pre-eclampsia, ease of 
measuring in clinical practice, and generalisability to 
different settings. We used backward selection, with a 
P value threshold of 0.2, to select variables for inclu-
sion in these early pregnancy characteristic models. 
Mean arterial pressure at the  initial visit was forced to 
be included in all of these prediction models. The 
early pregnancy characteristic model was called 
model 1. We then added mean arterial pressure at ges-
tational ages 20, 25, 28, 31, 34, or 36 weeks (each 
tested separately) to determine the added value of 
such measurements from 20 weeks in predicting out-
comes (model 2). In model 3 we added the difference 
between the woman’s measurement of mean arterial 
pressure at each gestational age and their normative 
value (that is, their deviation from their expected tra-
jectory for their BMI, parity, smoking status, and ini-
tial mean arterial pressure) to model 1. Finally, model 
4 combined models 2 and 3 by adding both the value 
of mean arterial pressure and the deviation from the 
normative value at each gestational age to model 1. 
Table B in appendix 1 gives a summary of variables 
included in each model. The areas under the receiver 
operating characteristics curves (ROCs) of the models 
were compared with a Wald test based on a boot-
strapped standard error for the difference between 
areas. For predictions at each gestational age, we 
included in prediction models only women who had 
not yet delivered and aimed to predict the develop-
ment of pre-eclampsia at any stage of pregnancy, any 
subsequent preterm births, and small for gestational 
age offspring measured at birth. Table C in appendix 1 
shows the cumulative number of women who had 
delivered at each gestational age. We also considered 
including all measurements of mean arterial pressure 
up to a given gestational age in prediction models 
rather than just the initial and the current measure 
but found no meaningful improvement in the area 
under the curve.
The parameters from the first stage multilevel model 
were then used to derive normative values of mean arte-
rial pressure at each gestational age in SWS and these 
were combined with parameters from the second stage 
logistic regression model developed in ALSPAC and 
applied to women in the SWS cohort to externally vali-
date our prediction model. The model parameters for all 
outcomes are given in appendix 2.
We assessed the predictive ability of these models 
using the area under the receiver operating character-
istic curve and the sensitivity, specificity, and positive 
and negative predictive values, together with positive 
and negative likelihood ratios. We assessed calibra-
tion by comparing the actual versus the predicted risk 
across 10ths of the risk score for each outcome. The 
prediction models were recalibrated for the SWS 
when necessary by adjusting the intercept and slope 
of the logistic regression model for this cohort (see 
appendix 2).33
We assessed the expected numbers of women out of 
an initial cohort of 1000 who would be classified as low 
risk and high risk if we were to use a sequential 
 screening strategy to rule out pre-eclampsia at each 
gestation considered up to 31 weeks. Model 1 was used 
at booking, followed by model 2 at 20, 25, 28, and 31 
weeks. We tested two thresholds for the screening strat-
egy (applying the same threshold of the risk score at 
each gestational age of testing), which were derived 
from the average threshold (across all gestational ages 
from 20 to 36 weeks) required to give sensitivities of 
95% and 99%, respectively, at each gestational age in 
ALSPAC. These thresholds were then applied to the SWS 
to produce a flowchart of the expected numbers of 
women in each group at each stage of testing.
All analyses were completed in Stata version 13.1 and 
multilevel models were fitted using MLwiN version 2.30 
through Stata using the runmlwin command.34
patient involvement
This paper is based on two prospective cohort studies 
that collect data from members of the general popu-
lation (not patients) on a large number of potential 
risk factors and health outcomes and that are used 
widely by the research community to examine a wide 
range of health related questions. Consequently no 
patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved 
in recruitment or the design and implementation of 
the study. There are no plans to involve patients in 
dissemination.
Results
Table 1 shows maternal and pregnancy related charac-
teristics in the imputed data pre-eclampsia status. 
Tables D and E in appendix 1 compare their distribu-
tions with observed data. Characteristics were generally 
similar in the imputed data compared with the observed 
data. Women in the SWS were more likely to be over-
weight or obese, to be nulliparous, to have had previous 
gestational hypertension or gestational diabetes, and to 
be of non-white ethnicity and were less likely to smoke 
or to have pre-existing hypertension, were shorter and 
older on average, and had higher initial mean arterial 
pressure than women in the ALSPAC cohort.
Table F in appendix 1 shows the unadjusted associa-
tions of each of the predictor variables with each of the 
outcomes.
prediction of pre-eclampsia
Table 2 shows the area under the receiver operating 
characteristic curves for prediction of pre-eclampsia 
for the model with only early pregnancy characteris-
tics and subsequent models adding mean arterial 
pressure at different gestational ages from 20 to 36 
weeks. The prediction model that included only early 
pregnancy maternal characteristics and first mean 
arterial pressure from the antenatal clinic had an area 
under the curve of around 0.77 in the development 
cohort (ALSPAC; model 1). This improved to 0.79 with 
addition of mean arterial pressure (model 2) at 
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20  weeks of gestation and became greater with 
increasing gestational age at which mean arterial pres-
sure was measured, being 0.88 at 36 weeks of gesta-
tion. In the validation cohort (SWS) areas under the 
curve were similar to those in the development cohort, 
but the earliest gestational age at which there was evi-
dence of an improvement in the area under the curve 
for model 2 compared with model 1 was at 28 weeks. 
We therefore focused on this gestational age when pre-
senting calibration and predictive statistics. Models 3 
and 4 performed similarly to model 2 at all gestational 
ages in ALSPAC and SWS (table G in appendix 1). Fig-
ure A in appendix 3 shows the ROC curves for all four 
models with mean arterial pressure measured at 28 
weeks in ALSPAC and SWS.
Table H in appendix 1 and figure 1  show the calibra-
tion of model 2 at 28 weeks’ gestation for prediction of 
pre-eclampsia at 10ths of the risk score in the validation 
cohort (SWS). The model tended to overestimate the risk 
of pre-eclampsia, especially at higher values of the risk 
score, suggesting that we needed to recalibrate the 
model. Recalibration details are given in the appendix 
2. After recalibration the risk of pre-eclampsia was well 
estimated by the model in the validation cohort (table H 
in appendix 1; fig 1).
Table 3  shows specificity, positive and negative pre-
dictive values, and positive and negative likelihood 
ratios at fixed sensitivities of 95% and 99% (meaning 
that 95% and 99% of women who developed pre-
eclampsia would test positive) in ALSPAC and SWS for 
model 2 at 28 weeks. At these high sensitivities, as 
expected, there was a high false positive rate (low 
specificity), though we also observed a high negative 
predictive value (about 1) and low negative likelihood 
ratio, suggesting a strong ability to rule out pre-ec-
lampsia in women who tested negative at these values 
of the risk score. Figure 2 shows the expected results of 
a sequential screening strategy to rule out pre-eclamp-
sia, testing with model 1 at booking and then with 
model 2 from 20 weeks onwards, with the threshold of 
the risk score set according to a sensitivity of 99% at 
each gestational age in ALSPAC, and the threshold 
applied in SWS. Women are moved into the low risk 
group at any gestational age at which they test nega-
tive for pre-eclampsia, and once in the low risk group 
women are not included in subsequent screens. Based 
on this approach it is expected that at 31 weeks, 27 out 
of 28 women who had not yet delivered and would go 
on to develop pre-eclampsia would be included in the 
high risk group and that just over a third of all of the 
women would have been allocated to the low risk 
group with a reduced care schedule. Figure B in 
appendix 3 shows the equivalent result with the 
threshold of the risk score that gave a 95% sensitivity 
in ALSPAC.
Table I in appendix 1 shows predictive statistics fix-
ing low false positive rates of 25%, 10%, and 5% (high 
specificities) for model 2 at 28 weeks. For a 5% false pos-
itive rate the sensitivity was 35% in ALSPAC and 32% in 
SWS, suggesting that the model had a weaker ability to 
rule in pre-eclampsia than to rule it out.
table 2 | prediction models for pre-eclampsia at different gestational ages in avon longitudinal Study of parents and 
Children (alSpaC) and Southampton women’s Survey (SwS) using imputed datasets. Figures are area under receiver 
operating characteristic curve (95% confidence intervals) 
gestational age 
of prediction 
(weeks)
development cohort (alSpaC) Validation cohort (SwS)
Model 1* Model 2†
p value  
for 2 v 1 Model 1* Model 2†
p value  
for 2 v 1
20 0.77 (0.75 to 0.80) 0.79 (0.77 to 0.82) 0.002 0.79 (0.73 to 0.85) 0.80 (0.74 to 0.85) 0.47
25 0.77 (0.75 to 0.80) 0.80 (0.77 to 0.82) <0.001 0.79 (0.73 to 0.85) 0.80 (0.75 to 0.86) 0.39
28 0.77 (0.75 to 0.80) 0.81 (0.79 to 0.84) <0.001 0.79 (0.73 to 0.85) 0.84 (0.79 to 0.88) 0.003
31 0.77 (0.74 to 0.79) 0.82 (0.80 to 0.85) <0.001 0.79 (0.73 to 0.85) 0.84 (0.79 to 0.89) 0.008
34 0.77 (0.74 to 0.80) 0.84 (0.82 to 0.87) <0.001 0.81 (0.75 to 0.87) 0.86 (0.81 to 0.90) 0.01
36 0.77 (0.74 to 0.80) 0.88 (0.86 to 0.90) <0.001 0.80 (0.74 to 0.87) 0.88 (0.84 to 0.93) <0.001
*Includes maternal covariates and mean arterial pressure at first visit.
†As model 1 plus observed value of mean arterial pressure for gestational age.
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Fig 1 | observed proportion of women who developed 
pre-eclampsia and 95% confidence interval in 10ths of 
predicted risk from model 2 at 28 weeks on original scale 
and with recalibrated model in Southampton women’s 
Survey (n=3005) with imputed datasets. Model 2 includes 
maternal covariates and mean arterial pressure at first visit 
and at 28 weeks
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Prediction of preterm birth
In both ALSPAC and the SWS, the model including only 
maternal characteristics in early pregnancy and mean 
arterial pressure at the initial visit had an area under 
the curve of 0.61 for prediction of preterm birth (model 
1; table J in appendix 1). There was little improvement 
from including the current mean arterial pressure 
(model 2) or the deviation of mean arterial pressure 
from the normogram (model 3) until 31 weeks’ gesta-
tion, when the area under the curve rose to 0.63 in 
ALSPAC for models 2 and 3. Similar areas under the 
curve were seen in the SWS, except that an improve-
ment was not seen until 34 weeks for models 2 and 3 
compared with model 1.
If we excluded cases of pre-eclampsia from our anal-
ysis, areas under the curve for prediction of preterm 
birth were generally slightly lower in both cohorts, but 
there remained an improvement from the addition of 
mean arterial pressure measurements from 31 weeks 
onwards in ALSPAC and at 34 weeks in SWS (table K in 
appendix 1).
Prediction of babies small for gestational age
In ALSPAC and SWS, the model including only maternal 
characteristics and mean arterial pressure at the initial 
visit had an are under the curve of around 0.70 for the 
prediction of small for gestational age (model 1; table L 
in appendix 1). Inclusion of either the current mean 
arterial pressure at any later gestational age (model 2) 
or deviation of mean arterial pressure from the normo-
gram (model 3) or both (model 4) did not improve this 
in ALSPAC or SWS.
discussion
principal findings
We have developed and compared prediction models 
for pre-eclampsia and two of its associated adverse 
outcomes—preterm birth and small for gestational 
age—using observed antenatal blood pressure mea-
surements (with diastolic and systolic entered into our 
models jointly as mean arterial pressure). We did this 
at varying gestational ages during pregnancy and 
externally validated these models in a similar large 
population based prospective pregnancy cohort. From 
28 weeks’ gestation onwards, the use of the current 
blood pressure in prediction models improved the 
identification of women who would develop pre-ec-
lampsia compared with using maternal characteristics 
measured in early pregnancy including the first mea-
surement; this could be used to facilitate stratified 
care. We found, however, that comparison against nor-
mograms allowing for distinctly different expected tra-
jectories of blood pressure across pregnancy for 
different subgroups of women based on pre-pregnancy 
BMI, parity, smoking, and initial blood pressure did 
not improve the discriminative ability of the prediction 
models compared with using the observed measure-
ment alone. Measures were of little value in predicting 
preterm birth until around 31 weeks’ gestation and did 
not aid in the prediction of small for gestational age at 
any gestational age after 20 weeks.t
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Study strengths and limitations
We used two large prospective cohort studies, one to 
develop the prediction models and the second to 
externally validate them. The detailed measurements 
of blood pressure in each of the studies allowed us to 
evaluate the predictive ability of these measurements 
at multiple gestational ages across pregnancy. We 
also used multiple imputation to maximise the sam-
ple size available. The ALSPAC pregnancies occurred 
over 20 years ago, and, as then, there might have been 
changes in clinical practice. The models, however, 
were validated in the SWS, where the pregnancies 
occurred more recently (8-16 years ago). Several of the 
predictor variables used were self reported so could 
be prone to measurement error. This is likely to reflect 
the way that information is obtained in clinical prac-
tice. We needed to recalibrate the prediction model 
for pre-eclampsia in the SWS. This is probably 
because of different definitions of pre-eclampsia in 
the two cohorts; in ALSPAC pre-eclampsia was 
defined by applying a standard definition to all mea-
surements of blood pressure and proteinuria in preg-
nancy whereas in SWS a record of a clinical diagnosis 
of pre-eclampsia during pregnancy was used. This 
suggests that the risk score requires recalibration 
according to different definitions of pre-eclampsia. 
The areas under the curve, however, were similar in 
the SWS to those in ALSPAC suggesting that the pre-
dictive ability of measurements of blood pressure in 
the second half of pregnancy is not dependent on the 
use of a particular definition of pre-eclampsia. The 
number of cases of pre-eclampsia in the SWS (n=88) 
was slightly lower than the recommended 100 events 
for validation,35 and our study might therefore have 
been slightly underpowered to detect differences in 
model fit. Despite this, our confidence intervals were 
of a reasonable width, and we were able to detect both 
the need for recalibration in SWS and an improve-
ment in the area under the curve for pre-eclampsia 
from the addition of blood pressure measures from 28 
weeks onwards in this cohort. We could not distin-
guish between medically indicated and spontaneous 
preterm births in our analyses, but our sensitivity 
analysis excluding women who had pre-eclampsia is 
likely to exclude most medically indicated preterm 
births related to high blood pressure.
Comparisons with other studies
The area under the curve for our prediction model for 
pre-eclampsia using mean arterial pressure at 28 
weeks was 0.81 in ALSPAC and 0.83 in SWS. This is 
higher than the area found in a model based on mater-
nal clinical risk factors (including mean arterial pres-
sure) in nulliparous women only in the SCOPE study at 
15 weeks’ gestation (0.76 in training dataset and 0.71 
after validation).15  Table M in appendix 1 shows the 
risk factors included in that model (not all of these 
were available in ALSPAC and SWS for us to compare 
our model directly with the SCOPE model). A recent 
systematic review identified 69 prediction models for 
pre-eclampsia but reported that only five of these had 
been externally validated.36  The validated models all 
included uterine artery Doppler measures or biomark-
ers that require laboratory testing that is not currently 
part of routine practice and is too expensive for use in 
low or middle income countries.21 37-40  Our prediction 
model uses readily available measures and allows for 
a sequential screening approach at each antenatal 
appointment that could be used in conjunction with 
screening in early pregnancy to update each woman’s 
risk estimate as pregnancy progresses. In a meta-anal-
ysis, mean arterial pressure in the second trimester 
was found to predict pre-eclampsia well, with an are 
under the curve of 0.76 in low risk populations.41 We 
have shown that this increases with gestation and that 
mean arterial pressure in the second half of pregnancy 
contributes additional predictive ability compared 
with using early pregnancy clinical characteristics 
alone.
Conclusions and policy implications
Current models of antenatal care focus on a series of 
repeat scheduled antenatal visits with recurrent 
screening for pre-eclampsia. In the UK, nulliparous 
Women at booking (n=1000; 29 will develop pre-eclampsia)
Women aer initial screen
(n=859; 29 will develop pre-eclampsia)
Women aer initial screen
(n=141; 0 will develop pre-eclampsia)
Women at 20 weeks
(n=806; 29 will develop pre-eclampsia)
Women at 20 weeks
(n=194; 0 will develop pre-eclampsia)
Negative test (n=53)
Delivered
(n=1; 0 with
pre-eclampsia)
Delivered
(n=1; 0 with
pre-eclampsia)
High risk groupLow risk group
Women at 25 weeks
(n=782; 29 will develop pre-eclampsia)
Women at 25 weeks
(n=218; 0 will develop pre-eclampsia)
Negative test (n=24)
Women at 25 weeks
(n=782; 29 will develop pre-eclampsia)
Women at 25 weeks
(n=218; 0 will develop pre-eclampsia)
Negative test (n=24)
Women at 28 weeks
(n=691; 29 will develop pre-eclampsia)
Women at 28 weeks
(n=307; 0 will develop pre-eclampsia)
Negative test (n=90)
Delivered
(n=3; 0 with
pre-eclampsia)
Delivered
(n=0; 0 with
pre-eclampsia)
Women at 31 weeks
(n=635; 27 will develop pre-eclampsia)
Women at 31 weeks
(n=360; 1 will develop pre-eclampsia)
Negative test (n=53)
Fig 2 | expected numbers of women allocated to low and high risk groups for pre-
eclampsia from cohort of 1000 women based on testing sequentially with model 1 at 
booking followed by model 2 at subsequent visits with threshold of 0.0047 at each 
gestational age up to 31 weeks. after initial screen, only high risk group are included in 
subsequent screening tests. to obtain these numbers we determined average threshold 
giving 99% sensitivity at each stage in alSpaC (including high risk group only after initial 
screen) and applied this threshold in SwS. Model 1 includes maternal covariates and 
mean arterial pressure at first visit; model 2 additionally includes mean arterial pressure 
at gestational age of testing
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women will have 12 healthcare assessments across 
gestation with nine of these visits occurring after 20 
weeks’ gestation, while multiparous women will 
have nine assessments with six occurring after 20 
weeks, missing appointments at 25, 31, and 40 
weeks.29  Similar stratified (based on parity) care 
occurs in other Western countries. A potential use of 
our model is for nulliparous women who are screened 
as low risk to be transferred to a reduced schedule 
similar to that of a multiparous woman. Conversely, it 
might be appropriate to transfer multiparous women 
screening as high risk to the more intensive schedule 
of a nulliparous woman. We have provided two exam-
ples of how care schedules could be altered in this 
way following sequential screening (fig 3 ). The deci-
sion of whether to increase the schedule of antenatal 
appointments for women testing as high risk versus 
decreasing the schedule for women classified as low 
risk, however, will depend on the setting and 
resources available for screening. A systematic 
review of randomised controlled trials that compared 
standard antenatal care with reduced care schedules 
found no difference in the rates of detection of 
pre-eclampsia in studies of low risk women in high 
income countries.42  Nevertheless, in low income 
countries the standard schedule of antenatal care 
might consist of only four visits across pregnancy, 
and a low proportion of women achieve full atten-
dance at these; here a focus on increasing the num-
ber of visits or increasing the awareness of the 
importance of these visits for women who screen as 
high risk might be most beneficial.43 It is also import-
ant to note that we have not taken into account rea-
sons for monitoring pregnant women other than 
pre-eclampsia, and these must also be considered 
when this care schedule is planned.
Further qualitative research is required to evaluate 
the views of clinicians and pregnant women on the 
frequency of antenatal care as many women find this 
regular contact with healthcare professionals reassur-
ing during pregnancy.42  This would inform the poten-
tial benefits and harms of different screening 
strategies and could be followed up with decision 
curve analysis to weigh these against each other.44  If 
the prediction models were to be used widely this 
would require the development of a tool for clinical 
use. Such a tool could be incorporated into a smart 
phone app, and future research could focus on evalu-
ating the use of this tool in low and middle income 
settings, in a similar way to the development and 
evaluation of tools for smart phones that has occurred 
in ophthalmology.45 46  Finally, extension of the mod-
els with additional measures such as the number and 
gestation of previous preterm deliveries or cervical 
length for preterm birth47  or first trimester serum con-
centrations of pregnancy proteins for small for gesta-
tional age,48 49 given that placental dysfunction is 
likely to underlie growth restriction, might be able to 
improve prediction of the adverse outcomes associ-
ated with pre-eclampsia.
In conclusion, measurements of blood pressure 
recorded during the second half of pregnancy, used in 
conjunction with blood pressure early in pregnancy 
and other maternal risk factors, can improve the identi-
fication of women who are at risk of developing pre-ec-
lampsia later in pregnancy and could be used to 
differentiate women who require more intensive moni-
toring from those who are likely to have a normal preg-
nancy. As there is little value in additionally using these 
later pregnancy measurements to predict preterm birth 
and small for gestational age, however, disease specific 
models will be required to facilitate stratified care for 
the range of pregnancy complications.
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